Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria — Stella

Recruiting

Back to Idiopathic Infantile Hypercalcaemia - Severe Form trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

Children's Hospital of Philadelphia

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrollment target

~60 participants

Started

July 2018

Primary completion

December 2026

Age range

6 Months – 65 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov